Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 5/20 | 0.41 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.41 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | NNMT | P40261 | 6/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947419 | 1.00 | UBA6 (0.41) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL936138 | 1.00 | UBA6 (0.41) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL1795550 | 0.90 | UBA6 (0.40) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL23892218 | 0.88 | PRMT5 (0.47) | UBA6NAE1PRMT5WDR77NNMT | |
| SCHEMBL16943624 | 0.86 | UBA6 (0.41) | UBA6PRMT5WDR77NNMT | |
| SCHEMBL191943 | 0.85 | ADK (0.48) | PRMT5WDR77 | |
| SCHEMBL10186224 | 0.85 | UBA6 (0.42) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL25048671 | 0.85 | UBA6 (0.42) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL19563037 | 0.85 | ADK (0.48) | PRMT5WDR77 | |
| SCHEMBL16769947 | 0.83 | PRMT5 (0.44) | UBA6PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| CN-101868461-B | Method for synthesizing E1 activating enzyme inhibitor | MILLENNIUM PHARM INC | 2013-09-25 | — | — | CN | disclosed |
| CN-102421780-A | Sulfamic acid ((1S,2S,4R) -4- {4- [ (1S) -2, 3-dihydro-1H-inden-1-ylamino ] -7H-pyrrolo [2,3-D ] pyrimidin-7-yl } -2-hydroxycyclopentyl) methyl ester hydrochloride | MILLENNIUM PHARM INC | 2012-04-18 | — | — | CN | disclosed |
| CN-101868461-A | Method for synthesizing E1 activating enzyme inhibitor | MILLENNIUM PHARM INC | 2010-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | UBA6 4470/4885NAE1 312/4885CA2 625/4885 |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | WASHC5, NME1, NHERF1 | UBA6 4510/4885NAE1 55/4885CA2 172/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | UBA6 4470/4885NAE1 312/4885CA2 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.